Overview
- A peer-reviewed paper published in Science on July 16, 2026 found that dendritic cell type 1 (DC1) is necessary to form and sustain tertiary lymphoid structures, organized immune clusters inside tumors.
- Researchers mapped DC1 presence across human lung, liver, colorectal, kidney, and ovarian tumors using multiplex imaging and spatial gene analysis to show these cells sit at the center of TLSs.
- A purpose-built mouse model gave causal evidence by showing that removing or impairing DC1 stops TLS formation and that timed DC1 depletion breaks down established TLSs.
- DC1 remain in tumors rather than traveling to lymph nodes and continually coordinate T cells and B cells, supporting local antigen presentation, antibody responses, and sustained immune activity.
- The work opens a translational path to therapies that raise DC1 numbers or activation to bolster immunotherapy and cut recurrence or metastasis, but the findings are preclinical and require further safety and efficacy studies.